KR20070067189A - 주사제에 유용한 베타-락타마제 억제제를 이용한베타-락타마제-매개 항생제 내성에 대처하기 위한 조성물 - Google Patents
주사제에 유용한 베타-락타마제 억제제를 이용한베타-락타마제-매개 항생제 내성에 대처하기 위한 조성물 Download PDFInfo
- Publication number
- KR20070067189A KR20070067189A KR1020077010375A KR20077010375A KR20070067189A KR 20070067189 A KR20070067189 A KR 20070067189A KR 1020077010375 A KR1020077010375 A KR 1020077010375A KR 20077010375 A KR20077010375 A KR 20077010375A KR 20070067189 A KR20070067189 A KR 20070067189A
- Authority
- KR
- South Korea
- Prior art keywords
- sodium
- composition
- sulbactam
- ceftriaxone
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 104
- 102000006635 beta-lactamase Human genes 0.000 title claims abstract description 17
- 108090000204 Dipeptidase 1 Proteins 0.000 title claims abstract description 15
- 230000003115 biocidal effect Effects 0.000 title claims abstract description 14
- 239000003781 beta lactamase inhibitor Substances 0.000 title claims abstract description 9
- 229940126813 beta-lactamase inhibitor Drugs 0.000 title claims abstract description 9
- 230000001404 mediated effect Effects 0.000 title claims abstract description 8
- 238000002347 injection Methods 0.000 title claims description 9
- 239000007924 injection Substances 0.000 title claims description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 52
- 229960005256 sulbactam Drugs 0.000 claims abstract description 37
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 claims abstract description 36
- 229960004755 ceftriaxone Drugs 0.000 claims abstract description 35
- 229960000479 ceftriaxone sodium Drugs 0.000 claims abstract description 35
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims abstract description 34
- FDRNWTJTHBSPMW-GNXCPKRQSA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-GNXCPKRQSA-L 0.000 claims abstract description 34
- NKZMPZCWBSWAOX-IBTYICNHSA-M Sulbactam sodium Chemical compound [Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)N2C(=O)C[C@H]21 NKZMPZCWBSWAOX-IBTYICNHSA-M 0.000 claims abstract description 33
- 229960000614 sulbactam sodium Drugs 0.000 claims abstract description 33
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 26
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 239000002738 chelating agent Substances 0.000 claims abstract description 7
- 238000007918 intramuscular administration Methods 0.000 claims abstract description 7
- 238000001990 intravenous administration Methods 0.000 claims abstract description 7
- 201000010099 disease Diseases 0.000 claims abstract description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims abstract description 5
- 230000010485 coping Effects 0.000 claims abstract description 3
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- 229960001484 edetic acid Drugs 0.000 claims description 28
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 26
- 239000011734 sodium Substances 0.000 claims description 26
- 229910052708 sodium Inorganic materials 0.000 claims description 26
- 239000002253 acid Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 10
- 239000008215 water for injection Substances 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 9
- 159000000000 sodium salts Chemical class 0.000 claims description 8
- -1 2-amino-4-thiazolyl Chemical group 0.000 claims description 7
- 239000011261 inert gas Substances 0.000 claims description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 6
- 229960003330 pentetic acid Drugs 0.000 claims description 6
- 208000035143 Bacterial infection Diseases 0.000 claims description 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 claims description 4
- 239000003125 aqueous solvent Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- JVKAWJASTRPFQY-UHFFFAOYSA-N n-(2-aminoethyl)hydroxylamine Chemical compound NCCNO JVKAWJASTRPFQY-UHFFFAOYSA-N 0.000 claims description 3
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 239000008227 sterile water for injection Substances 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 230000003385 bacteriostatic effect Effects 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229940000425 combination drug Drugs 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 229910001873 dinitrogen Inorganic materials 0.000 claims description 2
- 238000002309 gasification Methods 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- ZKUKMWMSYCIYRD-ZXFNITATSA-N lenampicillin Chemical compound O1C(=O)OC(COC(=O)[C@H]2C(S[C@H]3N2C([C@H]3NC(=O)[C@H](N)C=2C=CC=CC=2)=O)(C)C)=C1C ZKUKMWMSYCIYRD-ZXFNITATSA-N 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 229910052756 noble gas Inorganic materials 0.000 claims description 2
- 150000002835 noble gases Chemical class 0.000 claims description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 2
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 claims 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 239000003708 ampul Substances 0.000 claims 1
- 229940090047 auto-injector Drugs 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 239000008181 tonicity modifier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 11
- 239000003242 anti bacterial agent Substances 0.000 abstract description 5
- 229940088710 antibiotic agent Drugs 0.000 abstract description 4
- 239000002245 particle Substances 0.000 abstract description 3
- 239000002552 dosage form Substances 0.000 abstract description 2
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108020004256 Beta-lactamase Proteins 0.000 description 2
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940041009 monobactams Drugs 0.000 description 2
- 238000012859 sterile filling Methods 0.000 description 2
- 206010005940 Bone and joint infections Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- 239000008228 bacteriostatic water for injection Substances 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940124274 edetate disodium Drugs 0.000 description 1
- 238000009112 empiric therapy Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 150000002961 penems Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2411/DEL/2004 | 2004-12-02 | ||
| IN2411DE2004 | 2004-12-02 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097018388A Division KR101244362B1 (ko) | 2004-12-02 | 2005-11-28 | 주사제에 유용한 베타-락타마제 억제제를 이용한 베타-락타마제-매개 항생제 내성에 대처하기 위한 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20070067189A true KR20070067189A (ko) | 2007-06-27 |
Family
ID=35789266
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020077010375A Ceased KR20070067189A (ko) | 2004-12-02 | 2005-11-28 | 주사제에 유용한 베타-락타마제 억제제를 이용한베타-락타마제-매개 항생제 내성에 대처하기 위한 조성물 |
| KR1020097018388A Expired - Fee Related KR101244362B1 (ko) | 2004-12-02 | 2005-11-28 | 주사제에 유용한 베타-락타마제 억제제를 이용한 베타-락타마제-매개 항생제 내성에 대처하기 위한 조성물 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097018388A Expired - Fee Related KR101244362B1 (ko) | 2004-12-02 | 2005-11-28 | 주사제에 유용한 베타-락타마제 억제제를 이용한 베타-락타마제-매개 항생제 내성에 대처하기 위한 조성물 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8273732B2 (enExample) |
| EP (1) | EP1841432B1 (enExample) |
| JP (1) | JP5269415B2 (enExample) |
| KR (2) | KR20070067189A (enExample) |
| CN (1) | CN101060846A (enExample) |
| AT (1) | ATE476981T1 (enExample) |
| AU (1) | AU2005310888B2 (enExample) |
| BR (1) | BRPI0517128A (enExample) |
| CY (1) | CY1110886T1 (enExample) |
| DE (1) | DE602005022939D1 (enExample) |
| DK (1) | DK1841432T3 (enExample) |
| ES (1) | ES2349301T3 (enExample) |
| HR (1) | HRP20100591T1 (enExample) |
| MX (1) | MX2007006540A (enExample) |
| NZ (1) | NZ555075A (enExample) |
| PL (1) | PL1841432T3 (enExample) |
| PT (1) | PT1841432E (enExample) |
| RS (1) | RS51506B (enExample) |
| RU (1) | RU2397768C2 (enExample) |
| SI (1) | SI1841432T1 (enExample) |
| UA (1) | UA91204C2 (enExample) |
| WO (1) | WO2006059344A1 (enExample) |
| ZA (1) | ZA200704394B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10071113B2 (en) | 2012-03-26 | 2018-09-11 | Santen Pharmaceutical Co., Ltd. | Ophthalmic solution comprising diquafosol |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030010176A (ko) * | 2001-07-25 | 2003-02-05 | 이병두 | 은행 열매 추출물과 호도 열매 추출물을 이용한 천식 치료제 |
| CN101129382B (zh) * | 2006-08-25 | 2013-12-25 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和缓冲组分的抗生素复方 |
| CN101129381B (zh) * | 2006-08-25 | 2012-02-01 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和离子螯合剂的抗生素复方 |
| JP5639471B2 (ja) * | 2008-07-28 | 2014-12-10 | 惠三 山口 | 感染症治療効果増強剤 |
| CN101537009B (zh) * | 2009-04-30 | 2010-09-15 | 海口奇力制药股份有限公司 | 注射用头孢曲松钠他唑巴坦钠复方制剂的生产工艺 |
| JP2012176899A (ja) * | 2009-05-19 | 2012-09-13 | Mitsubishi Tanabe Pharma Corp | ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液 |
| PL2714034T3 (pl) * | 2011-05-28 | 2018-12-31 | Wockhardt Limited | Kompozycje zawierające cefepim i tazobaktam |
| MX362683B (es) * | 2011-07-26 | 2019-01-31 | Wockhardt Ltd | Composiciones farmacéuticas que comprenden antibiótico de beta-lactama, sulbactama e inhibidor de beta-lactamasa. |
| WO2013042140A2 (en) * | 2011-09-23 | 2013-03-28 | Manu Chaudhary | Non antibiotic,non peptide compounds for antibiotic efficacy & safety enhancement |
| MX365321B (es) | 2012-06-07 | 2019-05-29 | Los Angeles Childrens Hospital | Métodos para el tratamiento de neutropenia mediante agonistas retinoides. |
| WO2014052799A1 (en) * | 2012-09-27 | 2014-04-03 | Cubist Pharmaceuticals, Inc. | Tazobactam arginine antibiotic compositions |
| AU2015219038B2 (en) | 2014-02-18 | 2018-10-18 | Children's Hospital Los Angeles | Compositions and methods for treating neutropenia |
| EP3125887A1 (en) * | 2014-03-29 | 2017-02-08 | Wockhardt Limited | Pharmaceutical compositions comprising cefepime or sulbactam |
| CA2914314C (en) * | 2014-04-03 | 2021-05-18 | Baxter International Incorporated | Injection bag and injection preparation assembly |
| US10201518B2 (en) | 2016-09-28 | 2019-02-12 | The University Of Hong Kong | Bismuth(III) compounds and methods thereof |
| US10668079B2 (en) | 2016-11-02 | 2020-06-02 | Xiangbei Welman Pharmaceutical Co., Ltd. | Composition composed of ceftriaxone sodium and sulbactum sodium |
| CN111249284B (zh) * | 2016-11-03 | 2022-10-04 | 湘北威尔曼制药股份有限公司 | 治疗淋病奈瑟菌感染的头孢曲松钠舒巴坦钠 |
| RU2665006C1 (ru) * | 2017-02-28 | 2018-08-24 | Общество с ограниченной ответственностью "Супербаг Солюшенс" | Композиция антимикробных препаратов для лечения инфекционных заболеваний людей и животных и способ её применения |
| KR102790878B1 (ko) | 2018-08-09 | 2025-04-02 | 앤타바이오 에스에이에스 | 세린 베타-락타마제의 억제제로서 다이아자바이사이클로옥타논 |
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| KR20230121863A (ko) | 2020-12-17 | 2023-08-21 | 아이덱스 래보러토리즈, 인코포레이티드 | 로키산 홍반열 검출 및 치료 |
| WO2025165952A1 (en) * | 2024-01-31 | 2025-08-07 | The Penn State Research Foundation | Process for reduction of drug-resistant bacteria |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6630510B1 (en) * | 1999-10-28 | 2003-10-07 | Merck & Co., Inc. | Substituted succinic acid metallo-β-lactamase inhibitors and their use in treating bacterial infections |
| US6677320B2 (en) * | 2000-01-20 | 2004-01-13 | Hoffmann-La Roches Inc. | Parenteral bisphosphonate composition with improved local tolerance |
| ES2298672T3 (es) * | 2003-04-14 | 2008-05-16 | Wyeth Holdings Corporation | Composiciones que contienen piperacilina y tazobactam utiles para inyeccion. |
-
2005
- 2005-11-28 DE DE602005022939T patent/DE602005022939D1/de not_active Expired - Lifetime
- 2005-11-28 AT AT05817957T patent/ATE476981T1/de active
- 2005-11-28 KR KR1020077010375A patent/KR20070067189A/ko not_active Ceased
- 2005-11-28 BR BRPI0517128-8A patent/BRPI0517128A/pt not_active IP Right Cessation
- 2005-11-28 MX MX2007006540A patent/MX2007006540A/es active IP Right Grant
- 2005-11-28 ES ES05817957T patent/ES2349301T3/es not_active Expired - Lifetime
- 2005-11-28 EP EP05817957A patent/EP1841432B1/en not_active Expired - Lifetime
- 2005-11-28 HR HR20100591T patent/HRP20100591T1/hr unknown
- 2005-11-28 NZ NZ555075A patent/NZ555075A/en not_active IP Right Cessation
- 2005-11-28 WO PCT/IN2005/000382 patent/WO2006059344A1/en not_active Ceased
- 2005-11-28 DK DK05817957.3T patent/DK1841432T3/da active
- 2005-11-28 PT PT05817957T patent/PT1841432E/pt unknown
- 2005-11-28 PL PL05817957T patent/PL1841432T3/pl unknown
- 2005-11-28 SI SI200531130T patent/SI1841432T1/sl unknown
- 2005-11-28 RS RSP-2010/0465A patent/RS51506B/sr unknown
- 2005-11-28 KR KR1020097018388A patent/KR101244362B1/ko not_active Expired - Fee Related
- 2005-11-28 JP JP2007544016A patent/JP5269415B2/ja not_active Expired - Fee Related
- 2005-11-28 UA UAA200707280A patent/UA91204C2/ru unknown
- 2005-11-28 US US11/720,710 patent/US8273732B2/en not_active Expired - Fee Related
- 2005-11-28 AU AU2005310888A patent/AU2005310888B2/en not_active Ceased
- 2005-11-28 RU RU2007124325/15A patent/RU2397768C2/ru not_active IP Right Cessation
- 2005-11-28 CN CNA2005800395645A patent/CN101060846A/zh active Pending
-
2007
- 2007-05-29 ZA ZA200704394A patent/ZA200704394B/xx unknown
-
2010
- 2010-11-10 CY CY20101101012T patent/CY1110886T1/el unknown
-
2012
- 2012-09-25 US US13/626,236 patent/US9012442B2/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10071113B2 (en) | 2012-03-26 | 2018-09-11 | Santen Pharmaceutical Co., Ltd. | Ophthalmic solution comprising diquafosol |
| US10632139B2 (en) | 2012-03-26 | 2020-04-28 | Santen Pharmaceutical Co., Ltd. | Ophthalmic solution comprising diquafosol |
| US11166974B2 (en) | 2012-03-26 | 2021-11-09 | Santen Pharmaceutical Co., Ltd. | Ophthalmic solution comprising Diquafosol |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005310888A1 (en) | 2006-06-08 |
| JP5269415B2 (ja) | 2013-08-21 |
| WO2006059344B1 (en) | 2006-11-02 |
| HRP20100591T1 (hr) | 2010-12-31 |
| ES2349301T3 (es) | 2010-12-29 |
| RS51506B (sr) | 2011-06-30 |
| KR20090101514A (ko) | 2009-09-28 |
| SI1841432T1 (sl) | 2011-02-28 |
| RU2007124325A (ru) | 2009-01-10 |
| JP2008521884A (ja) | 2008-06-26 |
| EP1841432B1 (en) | 2010-08-11 |
| CN101060846A (zh) | 2007-10-24 |
| CY1110886T1 (el) | 2015-06-10 |
| RU2397768C2 (ru) | 2010-08-27 |
| WO2006059344A1 (en) | 2006-06-08 |
| DK1841432T3 (da) | 2010-12-06 |
| US9012442B2 (en) | 2015-04-21 |
| AU2005310888B2 (en) | 2011-01-06 |
| ATE476981T1 (de) | 2010-08-15 |
| KR101244362B1 (ko) | 2013-03-18 |
| MX2007006540A (es) | 2008-01-31 |
| PT1841432E (pt) | 2010-10-25 |
| NZ555075A (en) | 2011-02-25 |
| US8273732B2 (en) | 2012-09-25 |
| BRPI0517128A (pt) | 2008-09-30 |
| ZA200704394B (en) | 2008-09-25 |
| US20130023512A1 (en) | 2013-01-24 |
| PL1841432T3 (pl) | 2011-01-31 |
| EP1841432A1 (en) | 2007-10-10 |
| UA91204C2 (ru) | 2010-07-12 |
| US20100160277A1 (en) | 2010-06-24 |
| DE602005022939D1 (de) | 2010-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101244362B1 (ko) | 주사제에 유용한 베타-락타마제 억제제를 이용한 베타-락타마제-매개 항생제 내성에 대처하기 위한 조성물 | |
| US20200093814A1 (en) | Combination therapy with amidine substituted beta-lactam compounds and beta-lactamase inhibitors for infections with antibiotic resistant bacterial strains | |
| CN103648496B (zh) | 包含β-内酰胺抗生素、舒巴坦和β-内酰胺酶抑制剂的药物组合物 | |
| WO2013184845A1 (en) | Cyclic boronic acid ester derivatives and therapeutic uses thereof | |
| AU2013308128B2 (en) | Antibacterial compositions | |
| US20080227732A1 (en) | Treatment and Control of Severe Infections Including Cystic Fibrosis | |
| RU2521391C2 (ru) | Новые однократные единичные составы карбапенема и аминогликозида | |
| CN1582942A (zh) | 头孢呋辛钠复方制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0105 | International application |
Patent event date: 20070507 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20080725 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20090107 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20090701 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20090107 Comment text: Notification of reason for refusal Patent event code: PE06011S01I Patent event date: 20080725 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| J201 | Request for trial against refusal decision | ||
| PJ0201 | Trial against decision of rejection |
Patent event date: 20090803 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20090701 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20101230 Appeal identifier: 2009101007258 Request date: 20090803 |
|
| A107 | Divisional application of patent | ||
| AMND | Amendment | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20090902 |
|
| PB0901 | Examination by re-examination before a trial |
Comment text: Amendment to Specification, etc. Patent event date: 20090902 Patent event code: PB09011R02I Comment text: Request for Trial against Decision on Refusal Patent event date: 20090803 Patent event code: PB09011R01I Comment text: Amendment to Specification, etc. Patent event date: 20090311 Patent event code: PB09011R02I Comment text: Amendment to Specification, etc. Patent event date: 20080925 Patent event code: PB09011R02I |
|
| B601 | Maintenance of original decision after re-examination before a trial | ||
| PB0601 | Maintenance of original decision after re-examination before a trial | ||
| J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20090803 Effective date: 20101230 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S01D Patent event date: 20101231 Comment text: Trial Decision on Objection to Decision on Refusal Appeal kind category: Appeal against decision to decline refusal Request date: 20090803 Decision date: 20101230 Appeal identifier: 2009101007258 |
|
| J2X1 | Appeal (before the patent court) |
Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL |
|
| PJ2001 | Appeal |
Patent event date: 20101231 Comment text: Trial Decision on Objection to Decision on Refusal Patent event code: PJ20011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20111021 Appeal identifier: 2011201002060 Request date: 20110304 |
|
| J121 | Written withdrawal of request for trial | ||
| PC1202 | Submission of document of withdrawal before decision of registration |
Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment) Patent event code: PC12021R01D Patent event date: 20111111 |
|
| PJ1201 | Withdrawal of trial |
Patent event code: PJ12011R01D Patent event date: 20111111 Comment text: Written Withdrawal of Request for Trial Appeal identifier: 2009101007258 Request date: 20090803 Appeal kind category: Appeal against decision to decline refusal Decision date: 20101230 |
|
| WITB | Written withdrawal of application | ||
| J302 | Written judgement (patent court) |
Free format text: JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20110304 Effective date: 20111021 |
|
| PJ1302 | Judgment (patent court) |
Patent event date: 20111122 Comment text: Written Judgment (Patent Court) Patent event code: PJ13021S01D Request date: 20110304 Decision date: 20111021 Appeal identifier: 2011201002060 Appeal kind category: Appeal against decision to decline refusal |